Skip to main content
Advertisement
Advertisement
TGTX
TGTX logo
TG Therapeutics, Inc.
64.88
USD
Sponsored
-1.24
-1.88%
Nov 19, 15:59 UTC -5
Closed
exchange

After-Market

65.29

+0.41
+0.63%

TG Therapeutics, Inc. (TGTX) Earnings

TGTX Earnings Reports

Positive Surprise Ratio

TGTX beat 12 of 44 last estimates.

27%

Next Report

Date of Next Report
Jan 11, 2027
Estimate for Q4 26 (Revenue/ EPS)
$294.51M
/
$0.56
Implied change from Q3 26 (Revenue/ EPS)
+13.30%
/
+60.00%
Implied change from Q4 25 (Revenue/ EPS)
+52.93%
/
+300.00%

TG Therapeutics, Inc. earnings per share and revenue

On Nov 09, 2026, TGTX reported earnings of 0.35 USD per share (EPS) for Q3 26, missing the estimate of 0.37 USD, resulting in a -6.44% surprise. Revenue reached 259.94 million, compared to an expected 250.38 million, with a 3.81% difference. The market reacted with a +5.94% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of 0.56 USD, with revenue projected to reach 294.51 million USD, implying an increase of 60.00% EPS, and increase of 13.30% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Invivyd, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.13
Actual
-$0.10
Surprise
+26.47%
logo
Neumora Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.20
Actual
-$0.18
Surprise
+10.54%
logo
Instil Bio, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.17
Actual
-$0.62
Surprise
-261.09%
logo
AYTU BioPharma, Inc. Common Stock
Report Date
Nov 16, 2026 For Q1 27
Estimate
-$0.26
Actual
-$0.20
Surprise
+23.61%
logo
Estrella Immunopharma, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.17
Surprise
-108.33%
logo
Jasper Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$3.02
Actual
-$13.97
Surprise
-361.93%
logo
Kyntra Bio, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$3.61
Actual
-$3.42
Surprise
+5.49%
logo
Lantern Pharma Inc. Common Stock
Report Date
Nov 17, 2026 For Q3 26
Estimate
-$0.35
Actual
-$0.81
Surprise
-126.89%
logo
CNS Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.24
Surprise
+12.85%
logo
Pulmatrix, Inc. Common Stock
Report Date
Nov 17, 2026 For Q3 26
Estimate
-
Actual
-$0.34
Surprise
-
FAQ
For Q3 2026, TG Therapeutics, Inc. reported EPS of $0.35, missing estimates by -6.44%, and revenue of $259.94M, 3.81% above expectations.
The stock price moved up 5.94%, changed from $59.83 before the earnings release to $63.38 the day after.
The next earning report is scheduled for Jan 11, 2027.
Based on -- analysts, TG Therapeutics, Inc. is expected to report EPS of $0.56 and revenue of $294.51M for Q4 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement